Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer
| العنوان: | Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer |
|---|---|
| المؤلفون: | Muhammad H. Sultan, Sivakumar S. Moni, Osama A. Madkhali, Mohammed Ali Bakkari, Saeed Alshahrani, Saad S. Alqahtani, Nabil A. Alhakamy, Syam Mohan, Mohammed Ghazwani, Haitham A. Bukhary, Yosif Almoshari, Ahmad Salawi, Meshal Alshamrani |
| المصدر: | Scientific Reports, Vol 12, Iss 1, Pp 1-16 (2022) Scientific Reports |
| بيانات النشر: | Nature Portfolio, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Chitosan, Drug Carriers, Multidisciplinary, Cell Survival, Drug Compounding, Science, Antineoplastic Agents, Breast Neoplasms, Article, Drug Delivery Systems, Nanoscience and technology, MCF-7 Cells, Humans, Nanoparticles, Medicine, Cisplatin, Particle Size, Rituximab, Cancer |
| الوصف: | The present study was carried out to develop cisplatin-loaded chitosan nanoparticles (CCNP) and cisplatin-loaded chitosan nanoparticle surface linked to rituximab (mAbCCNP) as targeted delivery formulations. The two formulations (CCNP and mAbCCNP) exhibited significant physicochemical properties. The zetapotential (ZP) values of CCNP and mAbCCNP were 30.50 ± 5.64 and 26.90 ± 9.09 mV, respectively; while their particle sizes were 308.10 ± 1.10 and 349.40 ± 3.20 z.d.nm, respectively. The poly dispersity index (PDI) of CCNP was 0.257 ± 0.030 (66.6% PDI), while that of mAbCCNP was 0.444 ± 0.007 (57.60% PDI). Differential scanning calorimetry (DSC) revealed that CCNP had endothermic peaks at temperatures ranging from 135.50 to 157.69 °C. A sharp exothermic peak was observed at 95.79 °C, and an endothermic peak was observed at 166.60 °C. The XRD study on CCNP and mAbCCNP revealed distinct peaks at 2θ. Four peaks at 35.38°, 37.47°, 49.29°, and 59.94° corresponded to CCNP, while three distinct peaks at 36.6°, 49.12°, and 55.08° corresponded to mAbCCNP. The in vitro release of cisplatin from nanoparticles followed zero order kinetics in both CCNP and mAbCCNP. The profile for CCNP showed 43.80% release of cisplatin in 6 h (R2 = 0.9322), indicating linearity of release with minimal deviation. However, the release profile of mAbCCNP showed 22.52% release in 4 h (R2 = 0.9416), indicating linearity with sustained release. In vitro cytotoxicity studies on MCF-7 ATCC human breast cancer cell line showed that CCNP exerted good cytotoxicity, with IC50 of 4.085 ± 0.065 µg/mL. However, mAbCCNP did not elicit any cytotoxic effect. At a dose of 4.00 µg/mL cisplatin induced early apoptosis and late apoptosis, chromatin condensation, while it produced secondary necrosis at a dose of 8.00 µg/mL. Potential delivery system for cisplatin CCNP and mAbCCNP were successfully formulated. The results indicated that CCNP was a more successful formulation than mAbCCNP due to lack of specificity of rituximab against MCF-7 ATCC human breast cancer cells. |
| اللغة: | English |
| تدمد: | 2045-2322 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::269e219fdd5f3d4e8285c6531f709215Test https://doaj.org/article/3b3d5dd6f86b44c0b4cd0d6101fa0c5cTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....269e219fdd5f3d4e8285c6531f709215 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20452322 |
|---|